Shares of biopharmaceutical company Aurinia Pharmaceuticals Inc. (AUPH) are down 3 percent on Wednesday's trading despite there being no company news to impact the stock.
Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the company introduced the first FDA-approved oral therapy indicated for the treatment of adult patients with active lupus nephritis.
Currently at $22.58, the stock has traded between $9.72 and $33.97 during the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.